HGH Fragment 176-191 for Fat Loss: Reading the Data

HGH fragment 176-191 — also marketed as AOD-9604 — is one of the more carefully studied fat-loss peptides to have gone through clinical development and failed. It made it further than almost anything else in this category: through Phase 1 safety trials, into Phase 2 efficacy testing, and into a large Phase 3 obesity trial before it ran into the wall that most obesity drugs hit.

The failure doesn't make it useless. It makes the evidence picture more complicated than the research-chemical market typically presents it.

Where it comes from: the lipolytic fragment of GH

Human growth hormone is a 191-amino-acid protein. The molecule has distinct functional regions: the portions that drive tissue growth and protein synthesis, and the C-terminal region (amino acids 176–191) that appears to drive lipolysis — fat breakdown.

Researchers at Monash University in Melbourne, working in the late 1990s, isolated the C-terminal fragment to test whether it could deliver the fat-loss effects of GH without the diabetogenic effects (blood glucose elevation, insulin resistance) associated with full GH administration. The synthetic version of this fragment — sometimes called Tyr-hGH(177-191) to reflect the added tyrosine residue — became AOD-9604.

The hypothesis was clean: take the part of GH that burns fat, leave behind the parts that cause side effects. In animal models, it worked.

What the animal data showed

The preclinical rodent data for AOD-9604 was consistently positive:

• Obese mice treated with AOD-9604 showed significant reductions in body fat compared to controls, with effects comparable to full GH administration in terms of fat loss
• Unlike full GH, AOD-9604 did not raise fasting blood glucose or produce measurable insulin resistance in treated animals
• Lean mice treated with AOD-9604 showed minimal fat loss — suggesting the compound preferentially targets excess fat rather than producing global lipolysis
• Effects appeared to involve both beta-3 adrenergic receptor activation (which drives fat cell breakdown) and direct inhibition of fat cell lipogenesis (new fat formation)

The rodent data was the foundation for human trials. The Monash group, and later APEN Biopharmaceuticals (which developed AOD-9604 commercially), moved into human Phase 1 work on the strength of it.

The clinical development story

Phase 1 (safety): AOD-9604 was well-tolerated in healthy adult volunteers at doses from 1 mg to 12 mg administered subcutaneously. No serious adverse events. Blood glucose was unaffected — the clean glucose profile from animal models replicated in humans. That was an important early confirmation.

Phase 2 (efficacy signal): A small Phase 2 trial in obese adults showed some signals of visceral fat reduction at doses of 1 mg/day over 12 weeks compared to placebo. The effects were modest but statistically detectable. The trial was not powered to make definitive claims, but it was enough to justify Phase 3.

Phase 3 (the failure): A large, randomized, placebo-controlled Phase 3 trial — the kind required for drug approval — failed to meet its primary endpoint of significant weight reduction versus placebo. The drug did not produce the fat-loss effect in obese humans that the animal models predicted at the doses tested.

The failure was not unique to AOD-9604. It is a recurring pattern in obesity pharmacology: rodent models are poor predictors of human response for fat-loss interventions. The biology of obesity in ad-libitum-fed mice is genuinely different from obesity in humans with complex behavioral, metabolic, and hormonal factors.

After the Phase 3 failure, the compound was discontinued as a pharmaceutical development candidate and reverted to research-chemical status.

How it's used today

In the research-chemical market, HGH fragment 176-191 is sold as a lyophilized peptide for subcutaneous administration. The strength community uses it primarily in cutting protocols.

Reported protocols:

The fasted administration rationale is that GH-mediated lipolysis is enhanced in a low-insulin environment. Insulin blunts lipolytic signaling, so dosing before eating — when insulin is at baseline — is theorized to maximize the fat-burning window. This is the same reasoning behind fasted cardio.

The most commonly reported benefit in user logs is modest fat loss with preserved lean mass, particularly in the last 4–6 weeks of a cut when overall progress has stalled. The effects are described as subtle rather than dramatic — not a rapid body composition shift, but a noticeable change in how cutting protocol results look.

What the user experience can't isolate is how much of that effect is the peptide versus the caloric deficit, fasted cardio, and other elements of a cutting protocol running simultaneously. Without a controlled study, attribution is impossible.

What the Phase 3 failure means for users

The Phase 3 trial failure is often glossed over in the research-chemical market, but it is worth taking seriously.

The trial tested AOD-9604 in obese adults — a population with more metabolic dysfunction, more insulin resistance, and more complex hormonal profiles than the typical lean or moderately lean athlete running a peptide-assisted cut. It's plausible that AOD-9604 produces meaningful effects in already-lean individuals where the lipolytic mechanism operates against a healthier metabolic background.

It's also plausible that the Phase 3 result reflects a genuinely modest effect size that requires a caloric deficit to become apparent — and that the typical user running a deficit would have lost the fat anyway with or without the peptide.

The honest answer is that we don't have a well-powered clinical trial in the population actually using this compound. The Phase 3 data is what it is, and it is the best human evidence available.

Comparing to other fat-loss peptides

Tesamorelin is the only peptide in this comparison with FDA approval — specifically for visceral fat reduction in HIV-associated lipodystrophy. Its efficacy for visceral fat specifically is the most robustly supported by clinical trial data of anything in this category.

For athletes without visceral fat pathology trying to lean out, none of these compounds replace a structured caloric deficit and training protocol. They are potential adjuncts to an already-working approach, not standalone fat-loss solutions.

Reconstitution and practical use

Like most injectable peptides, HGH fragment 176-191 ships as a lyophilized powder and requires reconstitution with bacteriostatic water before injection.

Standard math: a 2 mg vial + 2 mL BAC water gives 1 mg/mL (1000 mcg/mL). A 250 mcg dose is 0.25 mL — or 25 units on a U-100 insulin syringe. The reconstitution calculator can work this out precisely for your vial size and target dose.

Injections are subcutaneous, typically abdominal. The compound is stable once reconstituted for about 3–4 weeks under refrigeration with bacteriostatic water.

For guidance on reading vendor quality documentation for any peptide you're considering, see how to read a certificate of analysis and vendor due diligence.

Related reading

• GH secretagogues for fat loss
• Tesamorelin visceral fat literature
• Reconstitution calculator
• Side effects overview